Literature DB >> 21915004

The cost of catheter-related bloodstream infections: implications for the value of prevention.

Christopher S Hollenbeak1.   

Abstract

Catheter-related bloodstream infections (CRBSIs) are frequently observed in the intensive care unit (ICU) and are a serious cause of morbidity and mortality in the United States. This article summarizes what is currently known about the cost of CRBSIs in the ICU setting. The cost of CRBSIs is between $33,000 and $44,000 in the general adult ICU, between $54,000 and $75,000 in the adult surgical ICU, and approximately $49,000 in the pediatric ICU. Finally, CRBSIs are associated with reimbursement that is more than $26,000 less than costs. Hospital and clinical decision makers should be aware of the high cost of CRBSIs in the ICU, the relatively poor reimbursement, and the implied high value of prevention efforts.

Entities:  

Mesh:

Year:  2011        PMID: 21915004     DOI: 10.1097/NAN.0b013e3182285e43

Source DB:  PubMed          Journal:  J Infus Nurs        ISSN: 1533-1458


  3 in total

1.  Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β-Lactam and Fluoroquinolone Concentrations.

Authors:  Iris H Chen; David P Nicolau; Joseph L Kuti
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

2.  Slippery Liquid-Like Solid Surfaces with Promising Antibiofilm Performance under Both Static and Flow Conditions.

Authors:  Yufeng Zhu; Glen McHale; Jack Dawson; Steven Armstrong; Gary Wells; Rui Han; Hongzhong Liu; Waldemar Vollmer; Paul Stoodley; Nicholas Jakubovics; Jinju Chen
Journal:  ACS Appl Mater Interfaces       Date:  2022-01-31       Impact factor: 10.383

3.  Central venous catheter-related bloodstream infection and colonization: the impact of insertion site and distribution of multidrug-resistant pathogens.

Authors:  Vassiliki Pitiriga; Petros Kanellopoulos; Ioannis Bakalis; Elsa Kampos; Ioannis Sagris; George Saroglou; Athanasios Tsakris
Journal:  Antimicrob Resist Infect Control       Date:  2020-12-01       Impact factor: 4.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.